Right now, the focus of is to make sure all readers are as UPDATED as possible on the Covid-19 pandemic.

Download our EXCLUSIVE report immediately at

It’s been said many times: the markets and the economy are not one and the same. Even with the global economic meltdown in the wake of the coronavirus pandemic, the stock market’s resilience has been truly stunning.

What’s been propping the stock market up lately? Among the most obvious culprits is the investing community’s undying optimism that a Covid-19 vaccine will be discovered, approved by regulators, and made available to the public in short order.

If you need proof that this is what’s holding up the stock market, check the price action of the S&P 500 and Dow Jones during the time when Dr. Fauci, the supposed expert on all things coronavirus-related, jawboned vaccine candidate remdesivir as if it were the answer to everyone’s problems.

Market participants bought into Fauci’s pitch hook, line, and sinker, and promptly bought up every large-cap stock in sight as if remdesivir were some sort of miracle drug. The problem is that Fauci jumped the gun and so did the markets. It’s a textbook lesson on what happens when someone sells a bill of goods to the public without telling the whole story.

While Fauci was busy calling remdesivir “the standard of care” based on a small sample of relatively healthy test subjects, an article from the New England Journal of Medicine revealed the shortcomings of the research study and exposed how limited the actual results were.

Specifically, the research showed no benefit with remdesivir for patients at most severe baseline status who were on non-invasive ventilation or intubated on a ventilator. No benefit was also shown for patients receiving extracorporeal membrane oxygenation.

Not only that, but there’s a safety issue with remdesivir as well as the New England Journal of Medicine article revealed, “Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization.” Moreover, the article reported a similar remdesivir clinical trial conducted in China which “was unable to demonstrate any statistically significant clinical benefits of remdesivir.”

Meanwhile, unlike Fauci with his half-baked claims, a company known as CytoDyn Inc. (OTCQB:CYDY) has the real deal. The difference-maker for CytoDyn’s Covid-19 vaccine candidate is a powerful component called leronlimab.

In a nutshell, leronlimab targets an important G protein coupled receptor called CCR5. CCR5 is more than just a pathway to HIV replication, but also a key mediator in many cancer metastasis (spreading) and a crucial component of inflammatory responses including ARDS, the main cause of mortality due to Covid-19 infection.

The Science Behind Leronlimab. Courtesy: CytoDyn Investor Presentation

Unlike the failed remdesivir, CytoDyn’s therapy drug candidate is truly on a fast track to success. A recent press release reports that “Leronlimab has been administered to 54 severely and critically ill COVID-19 patients thus far under Emergency Investigational New Drug (EINDs) authorizations granted by the U.S. Food and Drug Administration (FDA).”

The preliminary results from this patient population have already led to the FDA clearance for CytoDyn’s Phase 2b/3 clinical trial for 390 patients. These trials will be randomized and placebo-controlled; patients enrolled in this trial are expected to be administered leronlimab for two weeks.

93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.

Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!

Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!

    So far, CytoDyn’s stats have been highly promising:

    • FDA has approved 54 emergency IND
    • 49 patients have been injected so far
    • Many patients have been extubated and off of ventilators
    • Some patients have been discharged from the hospital with critical or severe COVID-19

    And now, CytoDyn is making its move against remdesivir. The company recently announced that it “will be submitting a protocol to the U.S. Food and Drug Administration (FDA) for a factorial design trial to compare effectiveness of leronlimab versus remdesivir and in combination with remdesivir for the treatment of COVID-19.”

    Jacob Lalezari, M.D., Chief Science Officer of CytoDyn, is eager to compare the results of the two proposed candidates. “We believe the randomized head-to-head comparison of leronlimab to remdesivir and in combination will provide answers to the lingering question regarding effective treatment options for patients suffering from COVID-19,” he explained.

    We already know the failings of remdesivir, so CytoDyn’s solution has the potential to not only be the winner – it could be an absolute landslide, with CytoDyn earning its place as the emerging leader in high-priority biotechnology solutions.

    EXCLUSIVE REPORTS, Featured In This Article and in Others, Which Are Considered ESSENTIAL READING:
    1. Gold Investing – DOWNLOAD HERE!
    2. Trump’s War with Mainstream Media – DOWNLOAD HERE!
    3. Covid-19 Round2 Sell-Off Playbook – DOWNLOAD HERE!
    4. Why The Dollar Is Dead – DOWNLOAD HERE!

    Best Regards,

    James Davis

    Governments Have Amassed ungodly Debt Piles and Have Promised Retirees Unreasonable Amounts of Entitlements, Not In Line with Income Tax Collections. The House of Cards Is Set To Be Worse than 2008! Rising Interest Rates Can Topple The Fiat Monetary Structure, Leaving Investors with Less Than Half of Their Equity Intact!

    Protect Yourself Now, By Building A Fully-Hedged Financial Fortress!

      We are not brokers, investment or financial advisers, and you should not rely on the information herein as investment advice. We are a marketing company. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on our communications. We own no shares and have no business relationship to any public company mentioned in this write-up. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC filings, press releases, and risk disclosures. Information contained in this profile was provided by the company, extracted from SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.

      Please read our full disclaimer at